Document Detail


Colesevelam HCl: a non-systemic lipid-altering drug.
MedLine Citation:
PMID:  12740000     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors). Although it is similar to other bile acid sequestrants in that it binds bile acids and is non-systemic, colesevelam HCl differs in that it has a unique polymer structure that allows for greater tolerability with less potential drug interactions than with resins. Currently, statins are the most commonly prescribed lipid-altering drugs. However, it is not uncommon that patients demonstrate true or perceived intolerances to statin therapy, that are often dose-related and may include elevations in liver or muscle enzyme blood levels, or myalgias or muscle weakness without muscle enzyme elevation. In rare circumstances, myopathy and even rhabdomyolysis can occur with statins. In addition, many statins also have important potential drug interactions. Finally, statin monotherapy is often not sufficient in achieving lipid treatment goals in many severely dyslipidaemic patients and the availability of colesevelam HCl provides a lipid-altering treatment addition to other lipid-altering drugs. From a clinical perspective, such combination therapy is often required to achieve treatment goals [1] in patients with more complicated or severe dyslipidaemia. Colesevelam HCl may also be an alternative in monotherapy for many patients with mild-to-moderate hypercholesterolaemia, as well as in some patients at potential risk from systemic exposure to alternative lipid-altering drugs (such as young children and fertile women).
Authors:
Harold Bays; Carlos Dujovne
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  4     ISSN:  1465-6566     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-12     Completed Date:  2003-07-22     Revised Date:  2008-04-14    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  779-90     Citation Subset:  IM    
Affiliation:
Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 12200 W 106th, Overland Park, KS 66215, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allylamine* / analogs & derivatives*,  metabolism,  pharmacokinetics,  therapeutic use
Animals
Antilipemic Agents* / metabolism,  pharmacokinetics
Child
Clinical Trials as Topic
Drug Interactions
Female
Half-Life
Humans
Hypercholesterolemia / drug therapy*
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 107-11-9/Allylamine; 182815-44-7/colesevelam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Paediatric community-acquired pneumonia: current concept in pharmacological control.
Next Document:  Safety and efficacy of tenecteplase in acute myocardial infarction.